The 32 references in paper S. NIKITIN S., Сергей Никитин Сергеевич (2015) “БЕССИМПТОМНАЯ ГИПЕРКРЕАТИНКИНАЗЕМИЯ В КЛИНИКЕ НЕРВНО-МЫШЕЧНЫХ БОЛЕЗНЕЙ // ASYMPTOMATIC ELEVATION OF CREATINE KINASE IN NEUROMUSCULAR DISEASES” / spz:neicon:nevro:y:2015:i:5:p:26-33

1
Kozlov A.V., Berestovskaya V.S., Rebyakova E.N. HyperKKemia as a laboratory marker. (part 1). Laboratornya diagnostica
(check this in PDF content)
2
12; 1:27-31 (Russian). (Козлов А.В., Берестовская В.С., Ребякова е.Н. ГиперКК как лабораторный маркер (часть 1). Лабораторная диагностика. 2012; 1: 27–31). 2. Kozlov A.V., Berestovskaya V.S., Rebyakova E.N. HyperKKemia as a laboratory marker. (part 2). Laboratornya diagnostica 2012; 1: 34–8. (in Russian) (Козлов А.В., Берестовская В.С., Ребякова е.Н. ГиперКК как лабораторный маркер (часть 2). Лабораторная диагностика. 2012; 1: 34–8).
(check this in PDF content)
3
Wong E.T., Cobb C., Umehara M.K., Wolff G.A., Haywood L.J., Greenberg T., Shaw S.T. Jr. Heterogenity of serum creatine kinase activity among racial and gender groups of the population. Am. J. Clin. Pathol. 1983; 79: 582–6.
(check this in PDF content)
4
rewster L.M., Coronel C.M.D., Sluiter W., Clark J.F., van Montfrans G.A. Ethnic differences in tissue creatine kinase activity: An observational study. PLoS One. 2012; 7(3): 1–3.
(check this in PDF content)
5
Black H.R., Quallich H., Gareleck C.B. Racial differences in serum creatine kinase levels. Am. J. Med. 1986; 81: 479–87.
(check this in PDF content)
6
Kyriakides T., Angelini C., Schaefer J., Sacconi S., Siciliano G., Vilchez J.J., Hilton-Jones D. EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia. Eur. J. Neurol. 2010; 17: 767–73.
(check this in PDF content)
7
Lilleng H., Abeler K., Johnsen S.H., Stensland E., Loseth S., Jorde R. et al. Variation of serum creatine kinase (CK) levels and prevalence of persistent hyperCKemia in a Norwegian normal population. The Tromso Study. Neuromusc. Dis. 2001; 21: 494– 500.
(check this in PDF content)
8
Duque A., Bagheri H., Lapeyre-Mestre M., Tournamille J.F., Sailler L., Dedieu G. et al. Detection and incidence of muscular adverse drug reactions: a prospective analysis from laboratory signals. Eur. J. Clin. Pharmacol. 2004; 60: 285–92.
(check this in PDF content)
9
Kleppe B., Reimers C.D., Altmann C., Pongratz D.E. Findings in 100 patients with idiopathic increase in serum creatine kinase activity. Med. Klin. 1995; 90: 623–7. сто среди заболеваний, которые следует включить в дифференциальный диагноз при бессимптомной гиперКК в связи с тем, что это единственная поясноконечностная миодистрофия, для которой разработаны и доступны патогенетическая терапия и методика рутинной малоинвазивной диагностики путем измерения активности альфа-глюкозидазы в сухом пятне крови. Для получения сухого пятна пригодна как капиллярная (из пальца), так и венозная кровь пациента, полученная с помощью шприца или вакуумной пробирки с ЭДТА. Капли крови наносят на специальные бумажные карточки, известные как DBS-карты, карты Guthrie или карты Whatman 903. Эти к
(check this in PDF content)
10
Simmons Z., Peterlin B.L., Boyer P.J., Towfighi J. Muscle biopsy in the evaluation of patients with modestly еlevated creatine kinase levels. Muscle and Nerve. 2003; 27: 242–4.
(check this in PDF content)
11
Reijneveld J.C., Notermans N.C., Linssen W.H., Bar P.R., Wokke J.H. Hyper-CK-aemia revisited. Neuromusc. Disord. 2001; 11: 163–4.
(check this in PDF content)
12
Kokotis P., Papadimas G.K., Zouvelou V., Zambelis T., Manta P., Karandreas N. Electrodiagnosis and muscle biopsy in asymptomatic hyperckemia. Int. J. Neurosci. 2015; Jul 14. Epub 2015 Jul 14.
(check this in PDF content)
13
Dabby R., Sadeh M., Herman O., Berger E., Watemberg N., Hayek S. et al. Y. Asymptomatic or minimally symptomatic hyperCKemia: histopathologic correlates. Isr. Med. Assoc. J. 2006; 8: 110–13.
(check this in PDF content)
14
Fernandez C., de Paula A.M., Figarella-Branger D., Krahn M., Giorgi R., Chabrol B.et al. Diagnostic evaluation of clinically normal subjects with chronic hyperCKemia. Neurology. 2006; 66: 1585–7.
(check this in PDF content)
15
Rowland L.P.W.J., Cerri C., DiMauro S., Miranda A. Approaches to the membrane theory of Duchenne muscular dystrophy. In: Angelini C., Danielli G.A., Fontanari D., eds. Muscular Dystrophy Researсh: Advances and New Trends, Amsterdam; 1980: 3–13.
(check this in PDF content)
16
Reijneveld J.C., Notermans N.C., Linssen W.H., Wokke J.H. Benign prognosis in idiopathic hyper-CK-emia. Muscle and Nerve. 2000; 23: 575–9.
(check this in PDF content)
17
D’Adda E., Sciacco M., Fruguglietti ME, Crugnola V, Lucchini V, Martinelli-Boneschi F. et al. J. Neurol. 2006; 253(11): 1399–403.
(check this in PDF content)
18
Prelle A., Tancredi L., Sciacco M., Chiveri L., Comi G.P., Battistel A.et al. Retrospective study of a large population of patients with asymptomatic or minimially symptomatic raised serum creatine kinase levels. J. Neurol. 2002; 249: 305–11.
(check this in PDF content)
19
Restivo D.A., Pavone V., Nicotra A. Single-fiber electromyography in hyperCKemia: the value of fiber density. Neurol. Sci.
(check this in PDF content)
20
2; 33(4): 819–24. 20. Filosto M., Tonin P., Vattemi G., Bertolasi L., Simonati A., Rizzuto N. et al. The role of muscle biopsy in investigating isolated muscle pain. Neurology. 2007; 68: 181–6.
(check this in PDF content)
21
Reijneveld J.C., Notermans N.C., Linssen W.H.J.P., Wokke J.H.J. Benign prognosis in idiopathic hyper-CK-emia. Muscle and Nerve. 2000; 23: 575–9.
(check this in PDF content)
22
Reijneveld J.C., Ginjaar I.B., Frankhuizen W.S., Notermans N.C. CAV3 gene mutation analysis in patients with idiopatic hyperCK-emia. Muscle and Nerve. 2006; 34: 656–8.
(check this in PDF content)
23
Tachi N., Wakai S., Yutoh Y., Chiba S. Asymptomatic hyperckemia: detection of isolated carrier of Duchenne muscular dystrophy. J. Child Neurol. 1990; 5: 351–3.
(check this in PDF content)
24
Afifi A. K. Idiopathic hyperCKemia revisited. J. Child Neurol. 1998; 13: 251–2.
(check this in PDF content)
25
Doriguzzi C., Palmucci L., Mongini T., Chiado-Piat L., Maniscalco M., Restagno G. Systematic use of dystrophin testing in muscle biopsies: results in 201 cases. Eur. J. ClinInvest. 1997; 27: 352–8.
(check this in PDF content)
26
Carbone I., Bruno C., Sotgia F., Bado M., Broda P., Masetti E.et al. Mutation in the CAV3 gene causes partial caveolin-3 deficiency and hyperCKemia. Neurology. 54: 1373–6, 2000.
(check this in PDF content)
27
Merlini L., Carbone I., Capanni C., Sabatelli P., Tortorelli S., Sotgia F. et al. Familial isolated hyperCKaemia associated with a new mutation in the caveolin-3 (CAV-3) gene. J. Neurol. Neurosurg. Psychiatry. 2002; 73: 65–7.
(check this in PDF content)
28
Morandi L., Angelini C., Prelle ., Pini A., Grassi B., Bernardi G. et al. High plasma creatine kinase: review of the literature and proposal for a diagnostic algorithm. Neurol. Sci. 2006; 27: 303–11.
(check this in PDF content)
29
Capasso M., De Angelis M.V., Di Muzio A., Scarciolla O. at al. Familial idiopathic hyper-CK-emia: an underrecognized condition. Muscle and Nerve. 2006; 33: 760–5.
(check this in PDF content)
30
Galbiati F., Razani B., Lisanti M.P. Caveolae and caveolin-3 in muscular dystrophy. Trends Mol. Med. 2001; 10(7): 435–42.
(check this in PDF content)
31
Bertorini T., Yeh Y.Y., Trevisan C., Stadlan E., Sabesin S., Didystrophy: V. Use of creatine kinase and pyruvate kinase in carrier detection. Muscle and Nerve. 1985; 8: 60–7. 51. Alias L., Gallano P., Moreno D., Pujol R., Martínez-Matos J.A., Baiget M. et al. A novel mutation in the caveolin-3 gene causing familial isolated hyperCKaemia. Neuromuscul. Disord. 2004; 14:
(check this in PDF content)
32
4. 52. Fanin M., Pegoraro E., Matsuda-Asada C., Brown R.H., Angelini C. Calpain-3 and dysferlin protein screening in patients with limb-girdle dystrophy and myopathy. Neurology. 2001; 56: 660–5.
(check this in PDF content)